-
Views
-
Cite
Cite
Carlton W. Thomas, , Brian G. Weinshenker, William J. Sandborn, Demyelination During Anti-Tumor Necrosis Factor α Therapy With Infliximab for Crohn's Disease, Inflammatory Bowel Diseases, Volume 10, Issue 1, 1 January 2004, Pages 28–31, https://doi.org/10.1097/00054725-200401000-00004
- Share Icon Share
Inflammatory demyelinating disease of the central nervous system may be linked to anti-tumor necrosis factor α therapy.
A 19-year-old female with Crohn's ileocolitis developed right arm and leg numbness and right hand weakness 4 weeks after the initiation of infliximab. Neurologic examination confirmed upper and lower right extremity sensory and motor deficits. MRI examination of the head and thoracic cord showed multiple gadolinium-enhancing lesions with distribution and configuration most suggestive of multiple sclerosis or other demyelinating process. The infliximab therapy was immediately stopped and follow-up at 8 weeks revealed symptomatic improvement.
This case report describes the onset of a demyelinating process after the institution of infliximab therapy in a patient with Crohn's disease.